Susquehanna International Group
ACRS icon

Susquehanna International Group’s Aclaris Therapeutics ACRS Stock Holding History

Susquehanna International Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Sell
379,930
-536,916
-59% -$1.81M ﹤0.01% 7018
2025
Q4 		$2.76M Buy
916,846
+880,609
+2,430% +$2.23M ﹤0.01% 5023
2025
Q3 		$68.8K Sell
36,237
-84,910
-70% -$148K ﹤0.01% 11747
2025
Q2 		$172K Sell
121,147
-1,260,594
-91% -$1.71M ﹤0.01% 11363
2025
Q1 		$2.11M Buy
1,381,741
+1,302,694
+1,648% +$2.78M ﹤0.01% 5405
2024
Q4 		$196K Buy
79,047
+16,639
+27% +$41.4K ﹤0.01% 10748
2024
Q3 		$71.8K Sell
62,408
-144,192
-70% -$177K ﹤0.01% 11225
2024
Q2 		$227K Buy
206,600
+83,140
+67% +$97.7K ﹤0.01% 10069
2024
Q1 		$153K Sell
123,460
-30,149
-20% -$36K ﹤0.01% 10886
2023
Q4 		$161K Buy
153,609
+29,759
+24% +$90.8K ﹤0.01% 10901
2023
Q3 		$848K Buy
123,850
+103,840
+519% +$887K ﹤0.01% 7007
2023
Q2 		$208K Sell
20,010
-8,466
-30% -$76.6K ﹤0.01% 10196
2023
Q1 		$230K Buy
+28,476
New +$361K ﹤0.01% 10288
2022
Q4 		– Sell
-22,536
Closed -$363K – 12263
2022
Q3 		$355K Buy
+22,536
New +$355K ﹤0.01% 9365
2022
Q2 		– Sell
-29,100
Closed -$408K – 12770
2022
Q1 		$502K Buy
29,100
+5,409
+23% +$73.8K ﹤0.01% 8955
2021
Q4 		$344K Buy
23,691
+10,574
+81% +$160K ﹤0.01% 10153
2021
Q3 		$236K Sell
13,117
-58,347
-82% -$935K ﹤0.01% 11128
2021
Q2 		$1.25M Sell
71,464
-376,171
-84% -$8.54M ﹤0.01% 7122
2021
Q1 		$11.3M Buy
447,635
+337,086
+305% +$6.59M ﹤0.01% 2595
2020
Q4 		$715K Buy
+110,549
New +$466K ﹤0.01% 7489
2020
Q1 		– Sell
-30,642
Closed -$58K – 10154
2019
Q4 		$58K Buy
30,642
+2,157
+8% +$3.58K ﹤0.01% 9305
2019
Q3 		$31K Sell
28,485
-42,408
-60% -$60.2K ﹤0.01% 9888
2019
Q2 		$155K Buy
70,893
+55,923
+374% +$305K ﹤0.01% 9342
2019
Q1 		$90K Buy
+14,970
New +$99.2K ﹤0.01% 8290
2018
Q3 		– Sell
-23,032
Closed -$460K – 9096
2018
Q2 		$460K Buy
23,032
+10,334
+81% +$191K ﹤0.01% 6957
2018
Q1 		$222K Sell
12,698
-60,396
-83% -$1.28M ﹤0.01% 8157
2017
Q4 		$1.8M Buy
+73,094
New +$1.78M ﹤0.01% 4086
2017
Q2 		– Sell
-33,793
Closed -$1.01M – 9103
2017
Q1 		$1.01M Buy
+33,793
New +$974K ﹤0.01% 5113

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group's ACRS Position: Q1 2026 in Review

Susquehanna International Group reduced its Aclaris Therapeutics (ACRS) stake by 59% in Q1 2026, selling an estimated $1.81M and leaving 379,930 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #7018.

Susquehanna International Group first reported a position in ACRS in Q1 2017 and has held it in 28 quarters since. The position peaked at $11.3M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Susquehanna International Group held 379,930 shares of Aclaris Therapeutics worth $1.42M as of Q1 2026.
  • Susquehanna International Group sold 536,916 Aclaris Therapeutics shares in Q1 2026, an estimated $1.81M.
  • Aclaris Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7018 holding.
  • Susquehanna International Group first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 28 quarters since.
  • Susquehanna International Group's Aclaris Therapeutics position peaked at $11.3M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.